Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Exelixis |
---|---|
Information provided by: | Exelixis |
ClinicalTrials.gov Identifier: | NCT00304590 |
This clinical study is being conducted at multiple sites to determine the activity, safety, and tolerability of XL999 when given weekly to patients with relapsed or refractory multiple myeloma. XL999 is a small molecule inhibitor of cellular factors including VEGFR, PDGFR, and FGFR that may be involved in multiple myeloma.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma |
Drug: XL999 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2 Study of XL999 in Subjects With Relapsed/Refractory Multiple Myeloma |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
Los Angeles, California, United States, 90095 | |
United States, Florida | |
Jacksonville, Florida, United States, 32207 | |
United States, Illinois | |
Chicago, Illinois, United States, 60637 | |
Joliet, Illinois, United States, 60435 | |
United States, Indiana | |
Indianapolis, Indiana, United States, 46202 | |
United States, New York | |
New York, New York, United States | |
United States, Texas | |
Fort Worth, Texas, United States, 76104 |
Study ID Numbers: | XL999-203 |
Study First Received: | March 16, 2006 |
Last Updated: | June 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00304590 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Immunoproliferative Disorders Hemorrhagic Disorders Hematologic Diseases Blood Protein Disorders Blood Coagulation Disorders Vascular Diseases |
Paraproteinemias Lymphoproliferative Disorders Hemostatic Disorders Neoplasms, Plasma Cell Multiple Myeloma |
Neoplasms by Histologic Type Immunoproliferative Disorders Immune System Diseases Blood Protein Disorders Hematologic Diseases Vascular Diseases Paraproteinemias |
Hemostatic Disorders Multiple Myeloma Neoplasms Hemorrhagic Disorders Cardiovascular Diseases Lymphoproliferative Disorders Neoplasms, Plasma Cell |